• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gut: Journal of the British Society of Gastroenterology >Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.
【24h】

Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.

机译：大肠癌患者血浆中microRNA的差异表达：大肠癌筛查的潜在标志物。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC). METHODS: This study was divided into three phases: (1) marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of five patients with CRC, along with plasma from five healthy individuals as controls; (2) marker selection and validation by real-time quantitative RT-PCR on a small set of plasma; and (3) independent validation on a large set of plasma from 90 patients with CRC, 20 patients with gastric cancer, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. RESULTS: Of the panel of 95 miRNAs analysed, five were upregulated both in plasma and tissue samples. All the five miRNAs were validated on the plasma of 25 patients with CRC and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in the patients with CRC (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 patients with CRC (p<0.05). Further validation with an independent set of plasma samples (n = 180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cut-off of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects. CONCLUSION: MiR-92 is significantly elevated in plasma of patients with CRC and can be a potential non-invasive molecular marker for CRC screening.
机译：目的：MicroRNA（miRNA）已显示出在癌症诊断中的巨大潜力。我们调查了血浆miRNA是否可以区分患有和没有结肠直肠癌（CRC）的患者。方法：该研究分为三个阶段：（1）使用基于实时PCR的miRNA分析在5名CRC患者的血浆，相应的癌性和邻近非癌性结肠组织以及5名健康个体的血浆中进行标记物发现控制; （2）在少量血浆上通过实时定量RT-PCR进行标记选择和验证; （3）对来自90例CRC患者，20例胃癌，20例炎症性肠病（IBD）和50例健康对照组的大量血浆进行独立验证。结果：在分析的95种miRNA中，有5种在血浆和组织样品中均被上调。在25名CRC患者和20名健康对照的血浆中验证了所有5种miRNA。 CRC患者的miR-17-3p和miR-92均显着升高（p <0.0005）。这些标志物的血浆水平在10例CRC患者术后显着降低（p <0.05）。用一组独立的血浆样品（n = 180）进一步验证表明，miR-92将CRC与胃癌，IBD和正常受试者区分开。该标记产生的接收器工作特性曲线面积为88.5％。截止值为240（与RNU6B snRNA相对表达），在将CRC与对照受试者区分开时，敏感性为89％，特异性为70％。结论：MiR-92在CRC患者血浆中显着升高，可能是CRC筛查的潜在非侵入性分子标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号